Analysis of the key themes driving M&A activity reveals that orphan designated drugs accounted for 34 pharmaceutical deals announced in Q3 2023, worth a total value of $13.5bn. The $7.3bn acquisition of Reata Pharmaceuticals by Biogen was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q3 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, orphan designated drugs-related deal activity increased by 39% in Q3 2023 compared with the previous quarter’s total of $9.7bn and fell by 8% as compared to Q3 2022. Related deal volume increased by 13% in Q3 2023 versus the previous quarter and was 10% higher than in Q3 2022.
The top-ranked financial advisors supporting these M&A deals in Q3 2023 were Centerview Partners; MTS Health Partners; SVB Financial Group with 10, 6, 4 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q3 2023 were Gibson, Dunn & Crutcher; Goodwin Procter; Cooley with 9, 9, 8 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q3 2023 – Thematic Intelligence, buy the report here.